SOLICITATION NOTICE
99 -- High Quality AAV Viral Preparations
- Notice Date
- 6/9/2017
- Notice Type
- Presolicitation
- NAICS
- 541712
— Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Institute of Allergy & Infectious Diseases/AMOB, 5601 Fishers Lane, 3rd Floor MSC 9822, Bethesda, Maryland, 20892, United States
- ZIP Code
- 20892
- Solicitation Number
- NIAID-NOI-B-1854285
- Archive Date
- 7/4/2017
- Point of Contact
- Merle J. Dixon, Phone: 240-669-5096, Julienne Keiser, Phone: 406-363-9370
- E-Mail Address
-
dixonmj@niaid.nih.gov, jkeiser@niaid.nih.gov
(dixonmj@niaid.nih.gov, jkeiser@niaid.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- This is a Notice of Intent, not a request for proposal. The Vaccine Research Center(VRC)/National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) intends to procure on an other than full and open competition basis with The Research Institute at Nationwide Children’s Hospital for High Quality AAV Viral Preparations with different vector serotypes (AAV1, AAV6) that have been purified and passed rigorous quality control standards. The Vaccine Research Center (VRC) requires high qual ity AAV viral preparations for use as a vaccine i n animal st udie s. The VRC i s devel oping vaccines against several respiratory pathogens t hat have g l obal health impact and for which a vaccine i s of utmost i mportanc e one of wh i ch is Respiratory Syncyt i al Virus (RSV). RSV i s relatively stable antigenically, yet mo s t adults are re -i nfected every fe w yea r s, s uggesti ng natural i mmunity i s not l ong- l astin g. Pa ssive i mmunizat i on i s used to prevent RSV i nfection in infants cons i dered at h i g h - risk for severe RSV i nfect i on, yet the majority of infan t s hospita l ized for RSV i nfect i on will not fall in t he hi gh-risk group. Studies have s hown that vector - mediated gene tran sfer (AAV) ha s great pr om i se i n vaccine de v e l opment d u e to its abi l ity to byp a ss the adapt i ve i mmune syst e m. Our st u d i es focus on construct i on of an AAV vector to del iver a RSV neutralizing antibody of choi ce and on ch aracterizing i n vivo production of t his antibody, asse ss whether it protect s against RSV challenge. To carry out our i n v ivo studies the VRC requi res a streamlined, trustworthy and repetitive product i on of AAV viral preparations for use i n an i mal stud i es, w h i ch i s only available through the Viral Vector Core at Nationwide Chi l dre n ' s Hospital.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/AMOB/NIAID-NOI-B-1854285/listing.html)
- Place of Performance
- Address: National Institutes of Health, Vaccine Research Center, Bldg. 40, Bethesda, Maryland, 20892, United States
- Zip Code: 20892
- Zip Code: 20892
- Record
- SN04540139-W 20170611/170609235120-db566d4bafb139a07bc507b5ccc00637 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |